KUSA – Beauty is only skin deep. Everyone knows that. But our actions don’t always reflect that understanding. For a clear picture of what that means we turn to the story of a teenager, yes a teenager. Seventeen-year-old Kelley Sperry is surrounded by peers that many of us might view...
Latest News
MEMPHIS, Tenn. – Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children’s Research Hospital and The University of Tennessee Health Science Center...
PARIS, France – Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results at the Myology 2024 international scientific congress, currently taking place in Paris. The trial combines phases...
Bethesda, MD — The American Gastroenterological Association (AGA) released a new evidence-based guideline recommending the use of blood and stool-based biomarkers to help manage Crohn’s disease, a type of inflammatory bowel disease (IBD). IBD is estimated to affect 2.74 million people in the U.S. The guideline was published today in...
PRINCETON, N.J. — Professor Julia Scarisbrick of the University of Birmingham on Friday, April 12, 2024, presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSE: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the...
Barcelona, Spain – Directed by Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program and head of our Models of Cancer Therapies Group, two decades of research aimed at combating resistance to therapy and cancer regression through inhibiting the MYC oncogene—found deregulated in most, if not all...
SYDNEY, Australia — Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY...
SHANGHAI, China — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is a single-arm, open-label, dose-escalation clinical...
LARKSPUR, Calif. — Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced dosing of the first patient in the initial Phase 2 expansion cohorts of its Phase 1/2 clinical trial evaluating AU-007 for treatment of unresectable locally advanced or metastatic...
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients. This phase 3 study, the first the evaluate avatrombopag in children, will evaluate efficacy, safety, and...